Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Carcinoma of the Ovary
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 12 Sep 2005 New trial record.